108 related articles for article (PubMed ID: 24050827)
21. Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study.
Briani C; Torre CD; Campagnolo M; Lucchetta M; Berno T; Candiotto L; Padua L; Ermani M; Cavaletti G; Zambello R
J Peripher Nerv Syst; 2013 Mar; 18(1):19-24. PubMed ID: 23521639
[TBL] [Abstract][Full Text] [Related]
22. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
23. Thrombomodulin improved liver injury, coagulopathy, and mortality in an experimental heatstroke model in mice.
Kawasaki T; Okamoto K; Kawasaki C; Sata T
Anesth Analg; 2014 May; 118(5):956-63. PubMed ID: 24781566
[TBL] [Abstract][Full Text] [Related]
24. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
[TBL] [Abstract][Full Text] [Related]
25. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.
Guglielmelli T; Bringhen S; Rrodhe S; Gay F; Cavallo F; Berruti A; Montefusco V; Piro E; Benevolo G; Petrucci MT; Caravita T; Offidani M; Corradini P; Boccadoro M; Saglio G; Palumbo A
Eur J Cancer; 2011 Apr; 47(6):814-8. PubMed ID: 21334196
[TBL] [Abstract][Full Text] [Related]
26. Neutrophilic dermatosis complicating lenalidomide therapy.
Thieu KP; Rosenbach M; Xu X; Kist JM
J Am Acad Dermatol; 2009 Oct; 61(4):709-10. PubMed ID: 19577327
[TBL] [Abstract][Full Text] [Related]
27. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
28. Lenalidomide, a thalidomide derivative, shows promise in various applications.
Oestreicher P
ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
[No Abstract] [Full Text] [Related]
29. Lenalidomide and venous thrombosis in multiple myeloma.
Rajkumar SV; Blood E
N Engl J Med; 2006 May; 354(19):2079-80. PubMed ID: 16696148
[No Abstract] [Full Text] [Related]
30. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
31. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone.
Corso A; Lorenzi A; Terulla V; Airò F; Varettoni M; Mangiacavalli S; Zappasodi P; Rusconi C; Lazzarino M
Ann Hematol; 2004 Sep; 83(9):588-91. PubMed ID: 15235749
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide and venous thrombosis in multiple myeloma.
Knight R; DeLap RJ; Zeldis JB
N Engl J Med; 2006 May; 354(19):2079-80. PubMed ID: 16687729
[No Abstract] [Full Text] [Related]
33. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
[TBL] [Abstract][Full Text] [Related]
34. Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.
Srinivasan S; Schiffer CA
Leuk Res; 2009 Apr; 33(4):561-4. PubMed ID: 18676017
[TBL] [Abstract][Full Text] [Related]
35. The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Bonkowski J; Vermeulen LC; Kolesar JM
J Oncol Pharm Pract; 2010 Dec; 16(4):223-32. PubMed ID: 19910392
[TBL] [Abstract][Full Text] [Related]
36. Lenalidomide in multiple myeloma: Current status and future potential.
Quach H; Kalff A; Spencer A
Am J Hematol; 2012 Dec; 87(12):1089-95. PubMed ID: 22641420
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Attal M; Lauwers-Cances V; Marit G; Caillot D; Moreau P; Facon T; Stoppa AM; Hulin C; Benboubker L; Garderet L; Decaux O; Leyvraz S; Vekemans MC; Voillat L; Michallet M; Pegourie B; Dumontet C; Roussel M; Leleu X; Mathiot C; Payen C; Avet-Loiseau H; Harousseau JL;
N Engl J Med; 2012 May; 366(19):1782-91. PubMed ID: 22571202
[TBL] [Abstract][Full Text] [Related]
38. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
Maier SK; Hammond JM
Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide: second cancers.
Prescrire Int; 2012 May; 21(127):130. PubMed ID: 22844687
[No Abstract] [Full Text] [Related]
40. Fatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma.
Tannemaat MR; Vries EP; Molendijk WJ; Haan J
Clin Neurol Neurosurg; 2011 Jul; 113(6):488-9. PubMed ID: 21315504
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
